Additional patent protection for Ygalo® granted in Japan until October 2033
The patent (application JP 2015-539556) covers inter alia the lyophilized formulation of Ygalo that is intended to be launched. The patent will expire in October 2033
"We are pleased to have received this patent notice which was in line with our expectations and it represents an important milestone for Ygalo’s future potential commercial value in this key territory. Last year a similar patent was granted in Europe, which increases the protection of Ygalo® beyond the composition of matter patent and orphan drug exclusivity periods" commented Jakob Lindberg, CEO Oncopeptides.
For further information, please contact:
Jakob Lindberg, CEO of Oncopeptides
Rein Piir, Head of Investor Relations at Oncopeptides
The information was submitted through the agency of the contact person above for publication at 08.00 CET on 8 March 2018.
Oncopeptides is a research and development stage pharmaceutical company developing drugs for the treatmentof cancer. The company focus on the development of the lead product candidate Ygalo®, an innovative, Peptidase Enhanced Cytotoxics (PEnCs). Ygalo® is intended for an effective treatment of hematological cancers, and in particular multiple myeloma. The current clinical study program is intended to demonstrate better results from treatment with Ygalo® compared to established alternative drugs for patients with late-stage multiple myeloma. Ygalo® could potentially provide physicians with a new treatment option for patients suffering from this serious disease.
Visit www.oncopeptides.se for more information.